Curis Inc Investor Relations Material
Latest events
Q4 2023
Curis Inc
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Curis Inc
Access all reports
Curis, Inc. is a biotechnology company focused on the discovery and development of drug candidates for the treatment of human cancers. The company's clinical stage drug candidate includes Emavusertib, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphoma, acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumor cancers and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate.
Key slides for Curis Inc
Corporate Presentation
Curis Inc
Corporate Presentation
Curis Inc
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States